Research programme: macrocyclic peptide therapeutics - Circle Pharma

Drug Profile

Research programme: macrocyclic peptide therapeutics - Circle Pharma

Alternative Names: Cancer therapeutics - Circle Pharma; CyclinA/Cdk2-targeting molecules - Circle Pharma; MCL1-targeting molecules - Circle Pharma

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Circle Pharma
  • Developer Circle Pharma; Pfizer
  • Class Antineoplastics; Macrocyclic compounds; Peptides
  • Mechanism of Action CXCR7 protein modulators; Cyclin modulators; Cyclin-dependent kinase 2 modulators; Intracellular signalling peptide and protein inhibitors; MCL1 protein modulators; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Nov 2017 Preclinical trials in Cancer in USA (PO)
  • 12 Sep 2016 Circle Pharma enters agreement with Pfizer to build a library of macrocyclic peptides
  • 30 Sep 2014 Research programme: macrocyclic peptide therapeutics - Circle Pharma is available for licensing as of 24 Sep 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top